{"entity":{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","aka":[],"tldr":"A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.","summary":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy is a phase 2 interventional study registered as NCT00377429 by Neovii Biotech, with 47 participants recorded, started 2006-09 and reaching its primary completion in 2008-02. Interventions recorded: catumaxomab. Conditions recorded: Ovarian Cancer.\n\nLinked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00377429","url":"https://clinicaltrials.gov/study/NCT00377429"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["catumaxomab"],"companies":["neovii"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00377429","phase":"2","setting":"An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy","sponsor":"Neovii Biotech","started":"2006-09","yearReported":2012,"enrolled":47,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions (Defined as 10-20-50-150 Micrograms) Within 21 Days","primary":true,"unit":"participants","arms":[{"name":"Catumaxomab","n":47,"value":29,"note":"Figures from the ClinicalTrials.gov results section (first posted 2012-07-11), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT00377429?tab=results"},{"endpoint":"Median Time of Progression-free Survival in Weeks (Post-study for 24 Months)","unit":"weeks","arms":[{"name":"Catumaxomab","n":43,"value":86.1,"note":"range 21.3 to 141.0; Figures from the ClinicalTrials.gov results section (first posted 2012-07-11), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT00377429?tab=results"}]},"route":"/trials/nct00377429/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/"}],"company":[{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/"}]}}